EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	JIN-A02 Sensitive: C2 – Inclusion Criteria JIN-A02 Sensitive : C2	JIN-A02 Sensitive: C2 – Inclusion Criteria JIN-A02 Sensitive : C2
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
EGFR C797S	Lung Cancer	EGFR C797S	Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	olmutinib Resistant: C3 – Early Trials olmutinib Resistant : C3	olmutinib Resistant: C3 – Early Trials olmutinib Resistant : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	rociletinib Resistant: C3 – Early Trials rociletinib Resistant : C3	rociletinib Resistant: C3 – Early Trials rociletinib Resistant : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	WZ4002 Resistant: C3 – Early Trials WZ4002 Resistant : C3	WZ4002 Resistant: C3 – Early Trials WZ4002 Resistant : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	cetuximab + brigatinib Sensitive: C3 – Early Trials cetuximab + brigatinib Sensitive : C3	cetuximab + brigatinib Sensitive: C3 – Early Trials cetuximab + brigatinib Sensitive : C3
EGFR C797S	Lung Adenocarcinoma	EGFR C797S	Lung Adenocarcinoma	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	bevacizumab + afatinib Sensitive: C3 – Early Trials bevacizumab + afatinib Sensitive : C3	bevacizumab + afatinib Sensitive: C3 – Early Trials bevacizumab + afatinib Sensitive : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	BBT-176 Sensitive: C3 – Early Trials BBT-176 Sensitive : C3	BBT-176 Sensitive: C3 – Early Trials BBT-176 Sensitive : C3

EGFR C797S

Associations